Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis.
Adult
Biomarkers
/ blood
Case-Control Studies
Elasticity Imaging Techniques
Female
Humans
Hypertension, Portal
/ blood
Liver
/ blood supply
Liver Cirrhosis
/ blood
Male
Middle Aged
Nogo Proteins
/ blood
Placenta Growth Factor
/ blood
Predictive Value of Tests
Prognosis
Prospective Studies
Severity of Illness Index
Angiogenesis
Hepatic venous pressure gradient
Liver cirrhosis
Nogo-A
Placental growth factor
Portal hypertension
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
21 Jun 2019
21 Jun 2019
Historique:
received:
23
03
2019
revised:
18
04
2019
accepted:
29
04
2019
entrez:
29
6
2019
pubmed:
30
6
2019
medline:
1
1
2020
Statut:
ppublish
Résumé
Clinically significant portal hypertension (CSPH) and severe portal hypertension (SPH) increase the risk for decompensation and life-threatening complications in liver cirrhosis. Pathologic angiogenesis might contribute to the formation of these conditions. Placental growth factor (PlGF) and Nogo-A protein are biomarkers of pathological angiogenesis, but data on their role in liver cirrhosis and portal hypertension is scarce. To determine plasma levels of PlGF and Nogo-A in patients with liver cirrhosis, CSPH, SPH and potential to predict portal hypertension. A cohort of 122 patients with hepatitis C virus and/or alcohol-induced liver cirrhosis with characterized hepatic venous pressure gradient (HVPG) were included in the study. Demographic data, medical history, Child-Turcotte-Pugh and Model of End Stage liver disease score, clinical chemistry, liver stiffness values were recorded on the day of the procedure prior HVPG measurement. The degree of portal hypertension was determined by the invasive HVPG measurement. Nogo-A and PlGF plasma levels were evaluated using enzyme linked immunosorbent assay. The control group consisted of 30 healthy age- and sex- matched individuals. Peripheral PlGF levels were higher and Nogo-A levels were lower in patients with liver cirrhosis (23.20 Plasma PlGF levels were higher while Nogo-A levels were lower in patients with liver cirrhosis and portal hypertension. Biomarkers showed moderate predictive value in determining CSPH and SPH.
Sections du résumé
BACKGROUND
BACKGROUND
Clinically significant portal hypertension (CSPH) and severe portal hypertension (SPH) increase the risk for decompensation and life-threatening complications in liver cirrhosis. Pathologic angiogenesis might contribute to the formation of these conditions. Placental growth factor (PlGF) and Nogo-A protein are biomarkers of pathological angiogenesis, but data on their role in liver cirrhosis and portal hypertension is scarce.
AIM
OBJECTIVE
To determine plasma levels of PlGF and Nogo-A in patients with liver cirrhosis, CSPH, SPH and potential to predict portal hypertension.
METHODS
METHODS
A cohort of 122 patients with hepatitis C virus and/or alcohol-induced liver cirrhosis with characterized hepatic venous pressure gradient (HVPG) were included in the study. Demographic data, medical history, Child-Turcotte-Pugh and Model of End Stage liver disease score, clinical chemistry, liver stiffness values were recorded on the day of the procedure prior HVPG measurement. The degree of portal hypertension was determined by the invasive HVPG measurement. Nogo-A and PlGF plasma levels were evaluated using enzyme linked immunosorbent assay. The control group consisted of 30 healthy age- and sex- matched individuals.
RESULTS
RESULTS
Peripheral PlGF levels were higher and Nogo-A levels were lower in patients with liver cirrhosis (23.20
CONCLUSION
CONCLUSIONS
Plasma PlGF levels were higher while Nogo-A levels were lower in patients with liver cirrhosis and portal hypertension. Biomarkers showed moderate predictive value in determining CSPH and SPH.
Identifiants
pubmed: 31249451
doi: 10.3748/wjg.v25.i23.2935
pmc: PMC6589742
doi:
Substances chimiques
Biomarkers
0
Nogo Proteins
0
PGF protein, human
0
RTN4 protein, human
0
Placenta Growth Factor
144589-93-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2935-2946Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors have declared no conflicts of interest.
Références
J Hepatol. 2001 May;34(5):644-50
pubmed: 11434609
Hepatology. 2001 Sep;34(3):487-93
pubmed: 11526533
J Neurosci. 2002 May 1;22(9):3553-67
pubmed: 11978832
Hepatology. 2004 Feb;39(2):280-2
pubmed: 14767976
Gastroenterology. 2004 Mar;126(3):886-94
pubmed: 14988842
Neurogastroenterol Motil. 2004 Aug;16(4):465-74
pubmed: 15306002
J Hepatol. 2005 Jul;43(1):98-103
pubmed: 15893841
Cancer Res. 2005 May 15;65(10):3967-79
pubmed: 15899784
Rev Esp Enferm Dig. 2005 Oct;97(10):699-706
pubmed: 16351462
Liver Int. 2006 Sep;26(7):889-98
pubmed: 16911473
Genome Biol. 2007;8(12):234
pubmed: 18177508
Hepatology. 2009 Apr;49(4):1245-56
pubmed: 19137587
J Hepatol. 2009 Mar;50(3):604-20
pubmed: 19157625
Gastroenterology. 2009 Dec;137(6):2112-24.e1-6
pubmed: 19751735
Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17511-6
pubmed: 19805174
J Hepatol. 2010 Sep;53(3):558-67
pubmed: 20561700
Blood. 2010 Dec 9;116(24):5423-33
pubmed: 20813898
PLoS One. 2011 Feb 14;6(2):e16978
pubmed: 21340026
J Mol Cell Cardiol. 2011 Jun;50(6):1044-55
pubmed: 21420413
Hepatology. 2011 Apr;53(4):1306-15
pubmed: 21480333
Hepatology. 2011 May;53(5):1629-40
pubmed: 21520176
Am J Med. 1990 Sep;89(3):335-44
pubmed: 2203263
Int J Hepatol. 2012;2012:691089
pubmed: 22720166
Cold Spring Harb Perspect Med. 2012 Aug 01;2(8):null
pubmed: 22908198
Proc Natl Acad Sci U S A. 2013 May 21;110(21):E1943-52
pubmed: 23625008
Am J Respir Cell Mol Biol. 2014 Aug;51(2):169-77
pubmed: 24568601
Hepatol Res. 2015 Jan;45(1):113-22
pubmed: 24606149
Mol Med Rep. 2014 May;9(5):1743-8
pubmed: 24626842
World J Gastroenterol. 2014 Dec 7;20(45):16811-9
pubmed: 25492995
J Hepatol. 2015 Sep;63(3):743-52
pubmed: 26047908
Mech Dev. 2015 Nov;138 Pt 1:26-36
pubmed: 26222953
Neurochem Res. 2015 Sep;40(9):1767-85
pubmed: 26266872
Ann Hepatol. 2016 May-Jun;15(3):303-13
pubmed: 27049484
Sci Rep. 2016 Oct 27;6:35969
pubmed: 27786289
Cell Mol Gastroenterol Hepatol. 2015 Jul 13;1(5):477-488
pubmed: 28210697
J Hepatol. 2017 Aug;67(2):399-411
pubmed: 28223101
PLoS One. 2017 Mar 16;12(3):e0173506
pubmed: 28301573
J Cell Mol Med. 2017 Oct;21(10):2370-2385
pubmed: 28378526
Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1300-1311
pubmed: 28408340
Gastroenterol Rep (Oxf). 2017 May;5(2):90-103
pubmed: 28533907
Front Immunol. 2017 Jul 11;8:801
pubmed: 28744285
Liver Int. 2018 Feb;38 Suppl 1:2-6
pubmed: 29427496
World J Gastroenterol. 2018 Sep 7;24(33):3738-3748
pubmed: 30197479